CHA2DS2 - Vasc Score Predict No Reflow Phenomenon in Primary Percutaneous Coronary Intervention
DOI:
https://doi.org/10.47672/ajhmn.1420Keywords:
CHA2DS2, VASc score, no reflow phenomenon, primary percutaneous coronary interventionAbstract
Purpose: ST-Elevation Myocardial Infarction is the most acute manifestation of Coronary artery disease, with substantial morbidity and mortality. Early reperfusion (re-establishing the blood flow in the occluded artery) is the most effective way to preserve the viability of the ischaemic myocardium and limit infarct size. Early diagnosis of STEMI is crucial to initiate appropriate treatment and should ideally be made within 10 minutes of first medical contact. This study aimed to evaluate the CHA2DS2-VASc score as a simple tool for predicting the no-reflow among patients with STEMI who underwent primary percutaneous coronary intervention.
Methodology: This was a case-control study which was conducted on 100 patients, diagnosed with acute STEMI and underwent primary PCI, who was admitted to Cardiology Department, Benha University Hospital and National Heart Institute. Patients were classified into two groups, control and no-flow, according to their final angiographic TIMI flow rates resulting from primary PCI. The control group: 78 patients with TIMI flow rate >2. The no-reflow group: 22 patients with TIMI flow rate ≤2, despite mechanical reopening of the infarct-related artery in patients without dissection of the coronary artery.
Findings: In this study, LVEF was significantly lower in patients with no-reflow compared to patients with normal TIMI flow (p <0.001), but LVEDV was significantly higher (p =0.01). There was no significant difference in LVESV between patients with no-reflow compared to patients with normal TIMI flow. CHA2DS2VASC score was significantly higher in patients with no-reflow compared to patients with normal TIMI flow (p <0.001). CHA2DS2VASC score is a significant predictor of occurrence of no reflow phenomenon (AUC: 0.689, p =0.006). At a cut off value of ≥ 2it has a sensitivity of 68.2%, specificity of 58.9%, PPV of 31.9% and NPV of 86.8%.
Recommendation: The study suggest that the CHA2DS2‑VASc score can be an independent predictor of no‑reflow phenomenon in patients undergoing primary PCI. As a simple and easy‑to‑calculate score, it might be a useful assessment tool to predict no‑reflow phenomenon before primary PCI interventions in patients with STEMI. Thus we recommend using CHA2DS2-VASc score as it is very simple and a quick tool to predict no-reflow before primary PCI
Downloads
References
Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am CollCardiol. 2011;58(24):2550–83.
Durante A, Camici PG. Novel insights into an old phenomenon: the no reflow. Int J Cardiol. 2015; 187:273–80.
Karimianpour A, Maran A. Advances in coronary no-reflow phenomenon-a contemporary review. CurrAtheroscler Rep. 2018; 20:44.
Chan YH, Yiu KH, Lau KK, Lam TH, Lau CP, Siu CW. The CHADS2 and CHA2DS2-VASc scores predict adverse vascular function, ischemic stroke and cardiovascular death in high-risk patients without atrial fibrillation: role of incorporating PR prolongation. Atherosclerosis. 2014;237(2):504–13.
Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P; ESC Scientific Document Group. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018 Jan 07;39(2):119-177.
Yunyun W, Tong L, Yingwu L, Bojiang L, Yu W, Xiaomin H, Xin L, Wenjin P, Li J. Analysis of risk factors of ST-segment elevation myocardial infarction in young patients. BMC CardiovascDisord. 2014 Dec 9;1 4:179.
Ye RG, Lu ZY, Xie Y, Wang C: Internal Medicine., China: People’s Medical Publishing House, 2006;918-6
Zhao J, Hu D-y, Ding R-j, Li XB, Zhang P, Wang L, Yu XJ, Guo JH, Wang XQ, Li L, Zhang FF, Huang ZW: Coronary characteristics of young smokers with coronary heart disease and the effects of tobacco control on smoking cessation [J]. Zhonghua Yi XueZaZhi. 2010, 38 (12): 1077-1080.
Nuttall FQ. Body Mass Index: Obesity, BMI, and Health: A Critical Review. Nutr Today. 2015 May;50(3):117-128.
Mirbolouk F, Gholipour M, Salari A, Shakiba M, Kheyrkhah J, Nikseresht V. CHA2DS2-VASc score predict no-reflow phenomenon in primary percutaneous coronary intervention in primary percutaneous coronary intervention. J CardiovascThorac Res. 2018; 10:46–52.
Niccoli G., Burzotta F., Galiuto L., Crea F. Myocardial no-reflow in humans. J Am CollCardiol. 2009; 54:281–292.
Celik T, Balta S, Ozturk C, Kaya MG, Aparci M, Yildirim OA. Predictors of no-reflow phenomenon in young patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Angiology. 2016; 67:683–9.
Fajar JK, Heriansyah T, Rohman MS. The predictors of no reflow phenomenon after percutaneous coronary intervention in patients with ST elevation myocardial infarction: a meta-analysis. Indian Heart J. 2018;70: S406–18.
Zhang QY, Ma SM, Sun JY. New CHA2DS2-VASc-HSF score predicts the no-reflow phenomenon after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. BMC CardiovascDisord. 2020 Jul 25;20(1):346.
Celermajer D.S., Sorensen K.E., Spiegelhalter D.J., Georgakopoulos D., Robinson J., Deanfield J.E. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am College Cardiol. 1994;24(2):471–476.
DeVore A.D., Schulte P.J., Mentz R.J. Relation of elevated heart rate in patients with heart failure with reduced ejection fraction to one-year outcomes and costs. Am J Cardiol. 2016;117(6):946–951.
Gürbak İ, Panç C, Şahin AA, Derviş E, Yıldız İ, Güler A, Demir AR, Kahraman S, Uzun F. CHA2DS2-VASc score as a predictor of no-reflow phenomenon after saphenous vein graft percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes. Kardiol Pol. 2020 Nov 25;78(11):1129-1136.
Ipek G, Onuk T, Karatas MB, Gungor B, Osken A, Keskin M. CHA2DS2-VASc Score is a Predictor of No-Reflow in Patients With ST-Segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Intervention. Angiology. 2016;67(9):840–5.
Modi R, Patted SV, Halkati PC, Porwal S, Ambar S, Mr P. CHA2DS2-VASc-HSF score - new predictor of severity of coronary artery disease in 2976 patients. Int J Cardiol. 2017; 228:1002–6.
Cetin M, Cakici M, Zencir C, Tasolar H, Baysal E, Balli M. Prediction of coronary artery disease severity using CHADS2 and CHA2DS2-VASc scores and a newly defined CHA2DS2-VASc-HS score. Am J Cardiol. 2014;1 13:950–6.
Bozbay M, Uyarel H, Cicek G, et al. CHA2DS2-VASc score predicts in-hospital and long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who were undergoing primary percutaneous coronary intervention. ClinApplThrombHemost 2017; 23:132–8.
Li CY, Chang CJ, Chung WJ, Lin CJ, Hsueh SK, Lee CH. Assessment of CHA2DS2-VASc score for predicting cardiovascular and cerebrovascular outcomes in acute myocardial infarction patients. Medicine (Baltimore). 2018;97:e11230.
Wang X, Pei C, Bai Y, Dai Q, Deng X, Liu Y. Predictive value of CHA2DS2-VASc score for ischemic events in patients undergoing percutaneous coronary intervention. Angiology. 2018; 70:878–86.
Iwakura K, Ito H, Ikushima M, Kawano S, Okamura A, Asano K. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am CollCardiol. 2003; 41:1–7.
Kim J, Cha M-J, Lee DH, Lee HS, Nam CM, Nam HS. The association between cerebral atherosclerosis and arterial stiffness in acute ischemic stroke. Atherosclerosis. 2011;219(2):887–91.
Harrison RW, Aggarwal A, Ou F, Klein LW, Rumsfeld JS, Roe MT. Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction. Am J Cardiol. 2012;111(2):178–84.
Iwakura K, Ito H, Kawano S, Shintani Y, Yamamoto K, Kato A. Predictive Factors for Development of the No-Reflow Phenomenon in Patients with Reperfused Anterior Wall Acute Myocardial Infarction. J Am CollCardiol. 2001;38(2):472–7.
Crea F, Camici PG, BaireyMerz CN. Coronary microvascular dysfunction: an update. Eur Heart J. 2014;35(17):1101–11.
Avci E, Yildirim T, Aydin G, Kiris T, Dolapoglu A, Kadi H. Combining clinical predictors to better predict for the no-reflow phenomenon. Eur Rev Med Pharmacol Sci. 2018;2 2:4987–94.
Bayramoglu A, AUID- Oho, Tasolar H, Kaya A, Tanboga IH, Yaman M. Prediction of no-reflow and major adverse cardiovascular events with a new scoring system in STEMI patients. J IntervCardiol. 2018; 31:144–9.
Mazhar J, Mashicharan M, Farshid A. Predictors and outcome of no-reflow post primary percutaneous coronary intervention for ST elevation myocardial infarction. Int J Cardiol Heart Vasc. 2016; 10:8–12.
Hassan A, Mohamed H, Mohamed AM, Ahmed T, Kishk YT. Predictors of no-reflow in patients undergoing primary percutaneous coronary intervention. Thrombus aspiration was protective. Egypt Heart J. 2018;70: 421–6.
Sanghvi S, Mathur R, Baroopal A, Kumar A. Clinical, demographic, risk factor and angiographic profile of coronary slow flow phenomenon: a single centre experience. Indian Heart J. 2018;70: S290–4.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Elsayed Abd Elkhalek Eldarky, Eman Saied Elkeshk, Amr Elsayed Elnager, Mikel Magdy Selim Soliman
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgment of the work’s authorship and initial publication in this journal.
